Sensyne Health’s CVm-Health+ ä software application to facilitate rapid COVID-19 antigen testing study by the University of Oxford
Omega Diagnostics Gp (ODX.L) Trading update and notice of interim results
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces the following trading update in advance of releasing its interim results for the six
Omega Diagnostics Gp (ODX.L) Notice of Trading Update and Investor Presentation
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it will release a trading update for the six months ended 30 September
Omega Diagnostics Gp (ODX.L) UK-RTC contract for the Supply of Goods
Agreed terms for the supply of goods by consortium members to fulfil UK Government orders Agreement also extends to the supply of other third-party customers, if permitted
Omega Diagnostics Gp (ODX.L) CE-Mark for Mologic COVID-19 antibody test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has CE-Marked Mologic Ltd’s (‘Mologic’) lateral flow antibody test for COVID-19 for
Omega Diagnostics Gp (ODX.L) WHO Prequalification received
VISITECT® CD4 Advanced Disease test receives WHO Prequalification
Omega Diagnostics Gp (ODX.L) Update on progress of UK-Rapid Test Consortium
CE Marking of COVID-19 lateral flow antibody test for professional use
Omega Diagnostics Gp (ODX.L) Update on progress of UK-Rapid Test Consortium
Significant progress in development with design freeze expected in June
Omega Diagnostics Gp (LON:ODX) COVID-19 Consortium MOU
Colin King, CEO of Omega commented: “We are delighted to be part of this consortium and to support the Scottish and UK Governments’ efforts to combat the Coronavirus pandemic and